International consensus guidelines report that the number of patients with adult congenital heart disease (ACHD) is steadily growing due to advances in surgical procedures and medical care, allowing more individuals with inborn malformations of their heart to live until adult age and beyond. 1, 2 In addition to ACHD lifelong cardiac condition and elevated somatic risk, some individuals also suffer from debilitating psycho-affective disorders, of which depression and anxiety are dominant. 3, 4 Symptoms of depression and anxiety, or their common denominator emotional distress, is considered a general risk factor for reduced quality of life, lower cardiac rehabilitation attendance, cardiac ischemic events and mortality. [5] [6] [7] [8] Moreover, life-course developed atherosclerotic disease is particularly prevalent in ACHD 9 and even subclinical atherosclerotic disease is aggravated in patients with symptoms of emotional distress. 10 It is thus of critical importance to accurately identify emotional distress in ACHD so that it can be effectively treated with psychotherapy and/or pharmacotherapy. Accurate diagnosing, however, require substantial resources in the form of specialised psychiatric personnel spending considerable time on comprehensive structured clinical interviewing, complex differential diagnostics, and symptom severity assessment. Such resources are often limited or unavailable in somatic care for ACHD. Cost-effective screening tools for depression and/or anxiety in ACHD therefore represents a pragmatic, first-line assessment option, given sufficient accuracy and effective administration.
In the present issue of European Journal of Preventive Cardiology, Westhoff-Bleck and co-authors 11 present a diagnostic evaluation of two well-known psychometric screening instruments for depression in adults with congenital heart disease. At a German clinic, 206 ACHD patients were administered the Hospital Anxiety and Depression Scale (HADS) and the Beck Depression Inventory (BDI-II) which were compared to blinded gold standard diagnosis of major depressive disorder of both mild (mMDD) and moderate to severe symptomatic form (msMDD). This diagnostic procedure was performed by experienced psychiatrists using the Structured Clinical Interview (SCID) for Axis I Disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Associated variables include depression symptom severity gauged with the observer version of the Montgomery-Å sberg Depression Rating Scale (MADRS) and quality of life measurements. A substantial portion of patients had MDD (25.7%). The researchers found that BDI-II, HADS total score, and the Depression subscale score of HADS (HADSD) were all accurate at identifying msMDD, but as to be expected, less accurate for correctly identifying mMDD. Overall, the three scales were excellent at classifying MDD regardless of symptom severity (AUC >.90). ACHD specific cut-offs for MDD are reported for the three evaluated scales.
The paper has several strengths. The sample size is relatively large (>200) given previous studies of the rare ACHD population. Furthermore, relatively few recruited patients were excluded. Most important is probably the use of the acknowledged gold standard diagnostic procedure with which the evaluated scales are compared, and clinical cut-offs derived. This is here done for the first time with ACHD and remedies the otherwise common limitation of psychometric scale research, which too often claims to validate a new self-report scale with another already validated self-report scale, but not with the gold standard diagnostic procedure.
Adding to the complexity of correct diagnostics is that symptom severity and prevalence estimates of MDD in ACHD are in part dependent on whether prevalence estimates are informed by basic screening tools or the more elaborate clinical assessment/structured diagnostic procedure. When the latter is used, a higher prevalence of anxiety and depression is reported for ACHD. 12, 13 The researchers highlight the role of symptom severity for diagnostic accuracy, and report substantial misclassification of depression in ACHD patients with only mild depressive symptomatology. This may be a substantial problem, given that mMDD constitutes roughly half of the total ACHD population with MDD, and because ACHD with only mMDD have reduced quality of life, and likely also a higher cardiovascular risk than ACHD without MDD.
International consensus guidelines 3, 4 suggest regular follow-up of ACHD patients at specialized centres. The most recent guidelines 3 also strongly recommend (class 1) that patients with ACHD be evaluated for depression and anxiety. The present evaluation of two screening instruments in this specific patient group is a welcome contribution that provides clinicians options of diagnostically evaluated instruments to use. These instruments are also reasonably brief, although an effective general screening might benefit from even shorter instruments. Low cut-off values can be argued for, accepting some false positives at the initial screening stage which psychiatric follow-up could thereafter effectively rule out. As depression and anxiety tend to be aetiologically multifactorial, a patient-centred, holistic treatment approach tailored to the individual patient is likely to be most beneficial, accounting also for the patient's psychosocial situation, cognitive functioning, and societal support, especially when transitioning from paediatric to adult care. It is also worth noting that screening does not have a value in itself if it does not lead to further actions or decisions. The recent guidelines from the American College of Cardiology/American Heart Association mention some high-impact but not fully answered research questions: Who should be screened for depression and anxiety, and what treatment is most effective? 3 Although psychological intervention seem to reduce psychological symptoms and cardiospecific mortality in patients with coronary artery disease, treatment findings are rather inconclusive [14] [15] [16] and predominantly unexplored in ACHD patients.
An important limitation not dealt with in the present paper is the fluctuation of mood disorders over time. Regular follow-up of ACHD would allow such monitoring as well, in part to evaluate if symptoms are newly developed, absent over time, remittent, or persistent. This might be motivated by the fact that major depression has an approximate 50% one-year spontaneous remission rate in the general population. 17 Moreover, although not examined in ACHD patients, different temporal trajectories of symptoms of anxiety and or depression in patients after an acute MI displayed diverging risks of mortality. 18 If investigated, ACHD may display a similar diverging pattern of risk dependent on psycho-affective temporality.
The authors correctly point out that the specific clinical cut-offs for MDD in ACHD are in need of external validation, since the study was single-site and the sample size did not allow for robust resampling. It is not certain that these exact cut-offs generalises to future ACHD or ACHD in other countries. As ACHD with MDD are rare, a pooled analysis of multi-centre data across nations seems particularly useful for the development of international norms for these instruments, possibly also with country-specific clinical cut-offs. Such international collaboration would allow for both (a) robust validation of the present diagnostic findings and (b) a thorough psychometric validation of the underlying factor structure of both HADS and BDI-II for ACHD. The latent factor structure may not necessarily be the same as in the general population. Future research will hopefully take this further, shedding light on the remaining gaps in our knowledge of the growing ACHD population and their psychoaffective challenges and possibilities. Having validated, high-quality screening instruments available is a precondition for dealing with the questions of implementation of interventions that can be of fundamental benefit to the patient.
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